Searched for
SANDOZ BIOSIMILARS
Sandoz bets big on biosimilars, aims to double group sales by 2035Sandoz plans to more than double annual net sales by 2035, with biosimilars leading growth. The company will expand its biosimilar portfoli...- Global Market: European shares slip as oil surge fuels inflation fears; Novartis plungesEuropean shares slipped as surging oil prices raised inflation concerns amid escalating Middle East tensions and threats to Gulf energy inf...
- Biocon arm gets Japan nod for cancer drug pegfilgrastim biosimilarIn a significant advancement, Biocon Biologics has gained marketing approval for its pegfilgrastim biosimilar in Japan. This vital cancer s...
- Lupin ties up with Sandoz to commercialise biosimilar productLupin has partnered with Sandoz Group AG to commercialize its biosimilar ranibizumab across multiple regions, with Sandoz handling commerci...
- Biocon Biologics focusing on market share gains of biosimilars in key marketsBiocon Biologics is focused on improving cash flows and increasing market shares of its biosimilar products, particularly in the US and Eur...
- Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in JapanAdalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylos...
- Intas in pact with Spanish drug maker mAbxience to sell biosimilar etanercept in over 150 countriesmAbxience, a majority-owned company of German drug maker Fresenius Kabi, also has partial ownership from Insud Pharma, will be responsible ...
- Biocon Biologics launches biosimilar adalimumab in USAdalimumab is used to treat certain inflammatory diseases like rheumatoid arthritis. Humira contributed $21.2 billion in sales to AbbVie fo...
- Novartis opens new manufacturing plant in Mumbai to make generic cancer drugsSpread across 32,000 sqm, and housing state-of-the-art production technology, the plant is built to cater to export markets. It currently h...
- Aurobindo’s buyout of Sandoz assets delayed on FTC queryOn Wednesday, shares of Aurobindo closed 4.8 per cent lower at Rs 450.75 on the BSE.
- Biocon’s $1-bn target for biologics biz achievable by FY22: Kiran Mazumdar ShawIn the next 10 years, there is great opportunity for cos that want to play in biosimilars.
- Aurobindo Pharma lines up $200 million capex for FY20Aurobindo Pharma Ltd. to invest $ 200 million on Capex and over 5% of sale value on R&D.
- Lupin-Mylan team up for biosimilar EtanerceptUnder the terms of the agreement, Lupin will receive an up-front payment of $15 million and potential commercial milestones together with a...
- Biocon Q3 net profit dips 46% to Rs 91.9 croreConsolidated revenue from operations of the company stood at Rs 1,057.9 crore for the quarter under consideration as against Rs 1,044.4 cro...
- Biocon runs up over 5% after Sandoz tie-upThe scrip was 3.23 per cent up at Rs 557.05 at around 10.20 am (IST) on the BSE.
- Biocon teams up with Swiss drugmaker Sandoz for next gen biosimilarUnder the terms of the agreement, both companies will share responsibility for end to end development, manufacturing and global regulatory ...
- Biocon teams up with Sandoz for next-gen BiosimilarsBiosimilars are identical copies of highly complex biologic drugs that are said to have the same efficacy.
- Claris Lifesciences gets USFDA drug approvalClaris Lifesciences Ltd, a parenteral drug company has received drug approval from US drug authorities for hypertension and angina treatmen...
- Ranbaxy plans to launch growth hormone drugRanbaxy Laboratories is planning a new growth hormone product to target the emerging global market for new versions of patent-expired biote...
- Wockhardt in talks with MNCs for biosimilar JVWockhardt is in talks with a clutch of multinational pharma companies, including Eli Lilly, Roche, Sandoz, Pfizer and Sanofi-Aventis, to fi...
Load More
